EraGen Biosciences Inc. Announces a Strategic Partnership, Licensing Agreement with Illumina, Inc.

MADISON, Wis.--(BUSINESS WIRE)--EraGen Biosciences Inc., a developer of novel molecular reagents for the in-vitro diagnostics (IVD) market, and Illumina Inc., a global company that develops, manufactures and markets integrated systems for analysis of genetic variation and biological function, today announced the formation of a strategic partnership and the execution of non-exclusive licensing agreements.